An observational study in Neoplasm Metastasis / Bone and Bones, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neoplasm Metastasis by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Neoplasm Metastasis · Assiut University.
Among the 11 studies in Neoplasm Metastasis by Assiut University, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 9th registered.
4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →7 of the 11 studies in Neoplasm Metastasis by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18+
Assiut University
Assiut University
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 84 is below the median of 137 across 560 observational studies indexed under Neoplasm Metastasis.
Median enrollment 20 across the 3 interventional studies, 79 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,088 studies on the registry; 2,185 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Neoplasm Metastasis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07904494Assiut UniversityImmune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma | 2027-10-01 |
| NCT07871253Assiut UniversityTherapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Neoplasm Metastasis by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bone metastases are a common and serious complication of cancer. Treatment response is currently judged mainly by delayed changes on CT scans or X-rays, a process that can take months and sometimes produces misleading results. The study investigates whether a specialized, radiation-free MRI technique called Dixon imaging can detect early signs of treatment response by measuring fat content within bone metastases before and after chemotherapy or radiotherapy. As tumor tissue within a bone lesion responds to treatment, the lesion is expected to be gradually replaced by fatty marrow, a change that can be quantified using the Dixon MRI method. Adult patients with a solid-tumor cancer and at least one lytic (bone-destroying) metastasis will undergo an MRI scan before starting treatment and a second MRI scan after completing chemotherapy or radiotherapy. Change in fat content within the lesion, and relative to normal marrow, will be measured and compared between patients receiving chemotherapy versus radiotherapy. The study does not involve additional radiation, contrast injection, or invasive procedures beyond standard MRI, and does not influence treatment decisions, which remain under the direction of the treating oncology team.
Adult patients with solid-tumor malignancy with ≥1 lytic bone metastasis (≥1 cm)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo 1.5 Tesla MRI examinations including conventional T1/T2-weighted sequences and a T1-weighted Dixon sequence, performed at two time points: at baseline, within one week prior to initiation of chemotherapy or radiotherapy, and again after completion of the treatment course. Fat-only and water-only Dixon image sets will be generated, and regions of interest will be placed on the target lytic bone metastasis and on a reference region of normal-appearing marrow. Relative fat fraction (rFF) will be calculated within each region from the ratio of fat-signal intensity to combined fat-and-water signal intensity, and a normalized fat fraction ratio (FFR) will be derived as lesion rFF divided by reference-region rFF. Diffusion-weighted imaging and apparent diffusion coefficient values will be obtained where feasible as an exploratory measure. No contrast agent, radiotracer, or ionizing radiation is administered as part of the imaging procedure, and no additional invasive
Change in Fat Fraction Ratio of Lytic Bone Metastases
Change in the normalized fat fraction ratio (FFR, lesion rFF divided by reference-region rFF), calculated as the difference between pre-treatment and post-treatment values for each participant.
Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course
Comparison of Change in Fat Fraction Ratio Between Chemotherapy and Radiotherapy Subgroups
Comparison of change in the normalized fat fraction ratio (FFR) between participants receiving chemotherapy versus radiotherapy
Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course
Inter-observer Agreement for Fat Fraction Ratio Measurements
Agreement between two independent observers' fat fraction ratio (FFR) measurements in a subset of re-measured lesions
Time frame: Baseline and a follow-up at 4 to 12 weeks after completion of the chemotherapy or radiotherapy course
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Mar 2029, 27 months later.
Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 27 months is below that.
Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.